VITASPRING BIOMEDICAL CO., LTD. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
VITASPRING BIOMEDICAL CO., LTD. (VSBC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $11.28 thousand for the 6-month period ending 2026-07-31, per its 10-Q filed 2026-09-17.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-09-17
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-04-30 was $6.08K.
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-04-30 was -$272.00, a 128.48% decline year-over-year.
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-04-30 was $955.00.
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-04-30 was -$26.66K.
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2026 was $1.81K, a 599.61% increase from fiscal 2025.
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $259.00.
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$29.64K.
- VITASPRING BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$77.56K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-07-31 | $11.28K 10-Q · filed 2026-09-17 | |||||
| 2026-04-30 | $6.08K 10-Q · filed 2026-06-17 | |||||
| 2026-01-31 | $1.81K 10-K · filed 2026-06-17 | |||||
| 2025-10-31 | $1.69K 10-Q · filed 2026-06-17 | |||||
| 2025-07-31 | $527.00 10-Q · filed 2026-09-17 | |||||
| 2025-04-30 | -$272.00 10-Q · filed 2026-06-17 | |||||
| 2025-01-31 | $259.00 10-K · filed 2026-06-17 | |||||
| 2024-10-31 | $2.05K 10-Q · filed 2026-06-17 | |||||
| 2024-07-31 | $5.51K 10-Q · filed 2026-06-17 | |||||
| 2024-04-30 | $955.00 10-Q · filed 2026-06-15 | |||||
| 2024-01-31 | -$29.64K 10-K · filed 2026-06-08 | |||||
| 2023-10-31 | -$27.02K 10-Q · filed 2026-05-06 | |||||
| 2023-07-31 | -$22.48K 10-Q · filed 2026-04-22 | |||||
| 2023-04-30 | -$26.66K 10-Q · filed 2026-04-02 | |||||
| 2023-01-31 | -$77.56K 10-K · filed 2026-03-12 | |||||
| 2022-10-31 | -$83.16K 10-Q · filed 2026-01-30 | $83.16K 10-Q · filed 2022-12-21 | ||||
| 2022-07-31 | -$85.62K 10-Q · filed 2026-01-23 | |||||
| 2022-04-30 | -$28.06K 10-Q · filed 2026-01-13 | |||||
| 2022-01-31 | -$292.63K 10-K · filed 2025-12-01 | $61.81K 10-K · filed 2022-05-03 | ||||
| 2021-10-31 | -$168.66K 10-Q · filed 2022-12-21 | |||||
| 2021-07-31 | $568.66K 10-Q · filed 2022-09-15 | |||||
| 2021-04-30 | $358.86K 10-Q · filed 2022-06-15 | |||||
| 2021-01-31 | $45.40K 10-K · filed 2022-05-03 |